(Q79920990)
Statements
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease (English)
Klaus Bendtzen
19 November 2007